ArticleIBRO neuroscience reports2025
Article in IBRO neuroscience reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Treatment for complex multifactorial neurological disorders may benefit more from multifunctional chemicals. Dysregulation of monoaminergic pathways and neuroinflammation are typical confluence points in a range of neuropsychiatric and neurodegenerative illnesses. Polypharmacological medications that affect neuroinflammatory and monoaminergic pathways were investigated as potential targets for these diseases. The aim of this study was to investigate the Methods: Decoction and hydro-ethanolic extracts were prepared and screened for their ability to inhibit enzymes related to inflammation (15-lipoxygenase, LOX), neurodegeneration (monoamine oxidase, MAO), and protein glycation and fibrillation using enzymological fluorimetric assays and docking simulations. Results: All extracts were able to strongly inhibit the activity of MAO as well as the glycation and fibrillation activities. Also, these extracts moderately inhibited 15-LOX activity. Conclusion: These results extend the knowledge on the potential use of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.